The stock in focus - Neumora Therapeutics Inc. (NMRA) is a clinical-stage biopharmaceutical company that engages in developing treatments for brain, neuropsychiatric, and neurodegenerative diseases in the U.S.
Its lead candidate, Navacaprant (NMRA-140), is a once-daily oral kappa opioid receptor antagonist currently in Phase 3 trials for major depressive disorder. The company is also advancing NMRA-511, now in Phase 1 trials for agitation associated with dementia due to Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.